Intrauterine Contraceptive Devices (IUCDs) Market Size, Share, Growth, and Industry Analysis, By Type (Hormonal Intrauterine Devices, Copper Intrauterine Devices), By Application (Hospitals, Gynecology Clinics, Community Healthcare Centers), Regional Insights and Forecast to 2035

Intrauterine Contraceptive Devices (IUCDs) Market Overview

The global Intrauterine Contraceptive Devices (IUCDs) Market size estimated at USD 3556.32 million in 2026 and is projected to reach USD 7849.1 million by 2035, growing at a CAGR of 9.2% from 2026 to 2035.

The Intrauterine Contraceptive Devices (IUCDs) Market is expanding steadily due to increasing awareness regarding long-acting reversible contraception and rising government-supported family planning programs. More than 159 million women globally used intrauterine contraceptive methods during 2025, with copper IUCDs accounting for 61% of total device utilization. Hormonal intrauterine devices represented 39% of market demand because of rising preference for low-maintenance contraceptive solutions. Hospitals contributed 48% of total device insertion procedures globally due to advanced gynecological care infrastructure. Europe accounted for 34% of worldwide IUCD utilization because contraceptive awareness programs and public healthcare reimbursement policies remained highly developed during 2025.

The United States Intrauterine Contraceptive Devices (IUCDs) Market showed substantial growth during 2025 due to increasing preference for long-term contraception among women aged 20 to 39 years. More than 14% of reproductive-age women in the United States used IUCDs during 2025, compared with 9% in 2018. Hormonal IUCDs accounted for 72% of total domestic demand because reduced menstrual bleeding and high contraceptive effectiveness influenced consumer preference. Gynecology clinics represented 44% of total insertion procedures nationwide due to improved outpatient contraceptive counseling services. California, Texas, Florida, and New York collectively contributed 38% of total U.S. IUCD procedures during 2025.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Approximately 68% of women preferred long-acting reversible contraception, while 59% prioritized highly effective birth control methods and 46% selected hormone-regulated contraceptive solutions.
• Major Market Restraint: Around 33% of women reported concerns regarding insertion discomfort, while 27% experienced fear of side effects and 19% lacked contraceptive awareness.
• Emerging Trends: Nearly 52% of new contraceptive programs focused on hormonal IUCDs, while 41% emphasized adolescent reproductive education and 36% promoted outpatient insertion services.
• Regional Leadership: Europe accounted for 34% of global demand, while North America represented 29% and Asia-Pacific contributed 26% of total utilization.
• Competitive Landscape: The top five manufacturers controlled 63% of organized market supply, while 48% expanded women’s reproductive healthcare partnerships globally.
• Market Segmentation: Copper intrauterine devices represented 61% of total demand, while hospitals accounted for 48% of insertion procedures globally.
• Recent Development: More than 43% of healthcare providers expanded same-day IUCD insertion programs between 2023 and 2025 globally.

Intrauterine Contraceptive Devices (IUCDs) Market Latest Trends

The Intrauterine Contraceptive Devices (IUCDs) Market is witnessing substantial transformation because long-acting reversible contraception adoption continues increasing worldwide. More than 159 million women globally used intrauterine contraceptive methods during 2025 because awareness regarding family planning and reproductive healthcare improved significantly. Hormonal intrauterine devices represented 39% of market demand because reduced menstrual bleeding and lower maintenance requirements increased patient preference globally. Copper IUCDs continued dominating with 61% share because non-hormonal contraceptive solutions remained highly preferred worldwide.

Hospitals accounted for 48% of insertion procedures because advanced gynecological infrastructure and trained healthcare professionals remained concentrated within hospital settings globally. Gynecology clinics additionally represented 37% of total procedures because outpatient contraceptive counseling expanded worldwide. Europe held 34% of market demand because public reimbursement systems and contraceptive awareness programs remained highly developed globally. North America accounted for 29% because insurance coverage and adolescent reproductive education improved worldwide. Postpartum IUCD insertion programs additionally increased by 28% during 2025 because hospitals promoted immediate contraceptive counseling globally. Community healthcare centers additionally improved access among low-income populations by 22% worldwide.

Intrauterine Contraceptive Devices (IUCDs) Market Dynamics

DRIVER

"Rising adoption of long-acting reversible contraceptive methods."

The Intrauterine Contraceptive Devices (IUCDs) Market is growing significantly because women increasingly prefer highly effective and long-term contraceptive methods globally. More than 68% of reproductive-age women preferred reversible contraceptive solutions during 2025 because of convenience and high effectiveness rates worldwide. Hormonal IUCD demand additionally increased by 31% because consumers preferred reduced menstrual symptoms and long-term birth control protection globally. Government-funded family planning programs additionally expanded contraceptive access across developing economies worldwide. Hospitals represented 48% of insertion procedures because trained gynecological specialists improved procedural safety globally. Community healthcare campaigns additionally increased contraceptive awareness among rural populations by 26% during 2025 worldwide. Europe accounted for 34% of market utilization because national healthcare systems provided subsidized contraceptive access globally. Postpartum contraceptive counseling additionally improved IUCD adoption by 24% worldwide.

RESTRAINT

"Concerns regarding insertion discomfort and side effects."

The Intrauterine Contraceptive Devices (IUCDs) Market faces restraints because some women continue reporting concerns regarding insertion discomfort and hormonal side effects globally. Approximately 33% of potential users expressed anxiety regarding device insertion during 2025 worldwide. Hormonal side effects additionally discouraged 27% of consumers because concerns regarding irregular bleeding and hormonal imbalance remained significant globally. Limited reproductive healthcare education additionally affected awareness among rural populations worldwide. Developing regions additionally demonstrated lower adoption because trained gynecological professionals remained limited globally. Community healthcare centers additionally faced shortages of contraceptive counseling staff in 18% of underserved regions worldwide. Social stigma regarding contraceptive usage additionally reduced adoption rates among younger women globally. Misinformation regarding infertility risks additionally influenced 16% of consumer hesitation during 2025 worldwide.

OPPORTUNITY

"Expansion of reproductive healthcare programs and outpatient gynecology services."

The Intrauterine Contraceptive Devices (IUCDs) Market presents strong opportunities because governments and healthcare providers continue expanding reproductive healthcare programs globally. More than 43% of healthcare systems introduced same-day IUCD insertion services during 2025 because outpatient contraceptive access improved worldwide. Gynecology clinics accounted for 37% of insertion procedures because private reproductive healthcare services expanded globally. Hormonal IUCD demand additionally increased among women aged 20 to 35 years by 29% worldwide. Asia-Pacific represented 26% of emerging opportunities because urban reproductive healthcare awareness improved rapidly globally. Community healthcare centers additionally expanded family planning programs by 21% during 2025 worldwide. Digital reproductive health consultation platforms additionally improved contraceptive counseling accessibility by 18% globally. Postpartum contraception initiatives additionally supported hospital-based insertion programs worldwide.

CHALLENGE

"Limited awareness and shortage of trained healthcare professionals."

The Intrauterine Contraceptive Devices (IUCDs) Market faces challenges because contraceptive awareness and trained insertion professionals remain unevenly distributed globally. Approximately 31% of rural healthcare facilities lacked trained gynecological insertion staff during 2025 worldwide. Community healthcare education additionally remained insufficient across developing economies globally. More than 24% of women lacked accurate information regarding IUCD effectiveness and reversibility worldwide. Supply chain limitations additionally affected contraceptive availability across remote healthcare centers globally. Public misconceptions regarding hormonal contraception additionally reduced adoption rates among younger consumers worldwide. Healthcare reimbursement limitations additionally affected affordability in 17% of low-income regions globally. Cultural resistance regarding contraceptive usage additionally restricted reproductive healthcare adoption in several emerging economies worldwide.

Intrauterine Contraceptive Devices (IUCDs) Market Segmentation

Download FREE Sample to learn more about this report.

The Intrauterine Contraceptive Devices (IUCDs) Market is segmented by device type and healthcare application, with copper intrauterine devices accounting for 61% of total global demand during 2025 because non-hormonal long-term contraception remained highly preferred worldwide. Hormonal devices represented 39% because reduced menstrual discomfort and high contraceptive effectiveness improved adoption globally. Hospitals accounted for 48% of insertion procedures due to advanced gynecological infrastructure worldwide. Gynecology clinics contributed 37% because outpatient contraceptive counseling services expanded significantly during 2025 globally.

BY TYPE

Hormonal Intrauterine Devices: Hormonal intrauterine devices accounted for 39% of market demand during 2025 because consumers increasingly preferred hormone-regulated contraception and reduced menstrual bleeding globally. Women aged 20 to 35 years represented 58% of hormonal IUCD users because long-term birth control convenience remained highly preferred worldwide. North America contributed 36% of hormonal IUCD utilization because insurance-supported reproductive healthcare services improved accessibility globally. Hospitals additionally represented 51% of hormonal device insertion procedures worldwide. Hormonal devices additionally reduced heavy menstrual bleeding among 42% of users during 2025 globally. Gynecology clinics additionally increased outpatient hormonal insertion procedures by 24% worldwide.

Copper Intrauterine Devices: Copper intrauterine devices dominated the market with 61% share during 2025 because hormone-free contraceptive solutions remained highly preferred globally. Europe contributed 35% of copper IUCD utilization because public reproductive healthcare systems supported non-hormonal contraception worldwide. Community healthcare centers additionally represented 29% of copper device insertions because low-cost family planning programs expanded globally. Women above age 30 accounted for 47% of copper IUCD users during 2025 worldwide. Copper devices additionally demonstrated effectiveness rates exceeding 99% during long-term contraceptive usage globally. Rural reproductive healthcare initiatives additionally improved copper IUCD access by 21% worldwide.

BY APPLICATION

Hospitals: Hospitals dominated the Intrauterine Contraceptive Devices (IUCDs) Market with 48% share during 2025 because advanced gynecological infrastructure and skilled healthcare professionals remained concentrated in hospital settings globally. Postpartum insertion programs additionally accounted for 31% of hospital procedures worldwide. North America represented 33% of hospital-based IUCD insertions because integrated reproductive healthcare systems improved accessibility globally. Hormonal devices additionally accounted for 54% of hospital insertions during 2025 worldwide. Same-day contraceptive counseling additionally improved patient conversion rates by 23% globally. Hospital maternity departments additionally expanded postpartum contraception initiatives worldwide.

Gynecology Clinics: Gynecology clinics accounted for 37% of total insertion procedures during 2025 because outpatient reproductive healthcare services expanded globally. Europe contributed 34% of clinic-based IUCD utilization because private gynecology consultations remained highly accessible worldwide. Hormonal intrauterine devices additionally represented 57% of clinic insertions because women preferred low-maintenance contraceptive solutions globally. Digital reproductive consultation services additionally improved appointment scheduling efficiency by 19% worldwide.

Community Healthcare Centers: Community healthcare centers represented 15% of the market during 2025 because public family planning programs improved contraceptive accessibility among low-income populations globally. Asia-Pacific contributed 32% of community healthcare utilization because government reproductive health initiatives expanded worldwide. Copper IUCDs additionally accounted for 68% of procedures because affordable non-hormonal contraception remained highly preferred globally. Rural healthcare outreach programs additionally improved awareness by 22% during 2025 worldwide.

Intrauterine Contraceptive Devices (IUCDs) Market Regional Outlook

Download FREE Sample to learn more about this report.

The Intrauterine Contraceptive Devices (IUCDs) Market demonstrates strong global growth because long-acting reversible contraception awareness and reproductive healthcare investments continue expanding worldwide. Europe accounted for 34% of global market demand during 2025 because subsidized reproductive healthcare systems remained highly developed globally. North America represented 29% because insurance coverage and outpatient gynecology services improved access worldwide. Asia-Pacific contributed 26% because family planning initiatives and urban healthcare infrastructure expanded rapidly globally. Middle East & Africa accounted for 11% because public reproductive healthcare programs gradually improved contraceptive accessibility worldwide.

NORTH AMERICA

North America accounted for 29% of the Intrauterine Contraceptive Devices (IUCDs) Market during 2025 because reproductive healthcare accessibility and contraceptive awareness remained highly advanced globally. The United States represented 82% of regional utilization because insurance-supported gynecological services improved affordability worldwide. Hormonal intrauterine devices accounted for 72% of North American demand because consumers preferred reduced menstrual bleeding and long-term contraception globally. Hospitals additionally represented 46% of insertion procedures because advanced maternity care infrastructure expanded worldwide. Gynecology clinics additionally contributed 41% of regional insertions because outpatient reproductive counseling improved significantly globally. Women aged 20 to 39 represented 61% of total IUCD users during 2025 worldwide. Same-day insertion programs additionally expanded by 27% across reproductive health clinics globally. Postpartum contraceptive counseling additionally improved adoption rates by 23% during 2025 worldwide.

EUROPE

Europe dominated the Intrauterine Contraceptive Devices (IUCDs) Market with 34% share during 2025 because contraceptive reimbursement systems and public reproductive healthcare programs remained highly advanced globally. Germany, France, the United Kingdom, and Nordic countries collectively represented 71% of regional demand worldwide. Copper intrauterine devices accounted for 58% of European utilization because non-hormonal contraception remained highly preferred globally. Community healthcare centers additionally represented 22% of regional insertion procedures because public healthcare accessibility remained strong worldwide. Hormonal device adoption additionally increased by 24% during 2025 because younger women increasingly preferred low-maintenance contraception globally. Government-supported reproductive education campaigns additionally improved awareness across universities and healthcare facilities worldwide. Postpartum insertion procedures additionally increased by 19% because hospital maternity programs strengthened globally. Digital contraceptive consultation platforms additionally improved gynecology appointment efficiency worldwide.

ASIA-PACIFIC

Asia-Pacific accounted for 26% of the Intrauterine Contraceptive Devices (IUCDs) Market during 2025 because government family planning initiatives and urban healthcare expansion improved contraceptive accessibility globally. China, India, Japan, and South Korea collectively represented 74% of regional demand worldwide. Copper IUCDs represented 69% of Asia-Pacific utilization because public healthcare systems promoted low-cost long-term contraception globally. Community healthcare centers additionally accounted for 33% of insertion procedures worldwide. Rural reproductive healthcare programs additionally improved contraceptive awareness by 28% during 2025 globally. Hospitals additionally expanded postpartum IUCD insertion services across maternity departments worldwide. Urban women aged 25 to 40 represented 49% of total Asia-Pacific IUCD users because workforce participation and delayed pregnancies increased globally. Digital reproductive education campaigns additionally improved family planning awareness worldwide.

MIDDLE EAST & AFRICA

The Middle East & Africa accounted for 11% of the Intrauterine Contraceptive Devices (IUCDs) Market during 2025 because public healthcare reforms and women’s reproductive health awareness gradually improved globally. Gulf countries represented 46% of regional utilization because private healthcare investments increased worldwide. Hospitals accounted for 52% of insertion procedures because advanced gynecological services remained concentrated in urban healthcare facilities globally. Copper IUCDs additionally represented 63% of regional utilization because affordable contraceptive methods remained highly preferred worldwide. Community healthcare initiatives additionally improved contraceptive counseling by 17% during 2025 globally. Urban reproductive healthcare centers additionally expanded hormonal device access worldwide. Maternal health programs additionally increased postpartum insertion procedures by 14% globally. Public reproductive health awareness campaigns additionally strengthened contraceptive education across several African healthcare systems worldwide.

List of Top Intrauterine Contraceptive Devices (IUCDs) Companies

• Agile Therapeutics
• Bayer Healthcare
• Fuji Latex Co. Ltd
• Pfizer
• Reckitt Benckiser Group PLC
• Mylan Laboratories
• Merck & Co.
• Okamato Industries Inc.

List of Top 2 Companies Market Share

• Bayer Healthcare: accounted for approximately 29% of organized Intrauterine Contraceptive Devices (IUCDs) Market demand during 2025 because hormonal intrauterine devices remained highly utilized globally.
• Merck & Co.: represented nearly 16% of global market share because reproductive healthcare product expansion and contraceptive partnerships strengthened worldwide.

Investment Analysis and Opportunities

The Intrauterine Contraceptive Devices (IUCDs) Market is attracting increasing investments because long-acting reversible contraception and reproductive healthcare accessibility continue improving globally. More than 44% of reproductive healthcare investments during 2025 focused on family planning infrastructure and contraceptive accessibility worldwide. North America accounted for 31% of healthcare investments because outpatient gynecology services and insurance-supported contraception programs expanded globally. Hormonal intrauterine devices additionally represented 39% of reproductive product investment activities worldwide. Asia-Pacific contributed 28% of emerging opportunities because public family planning programs and urban healthcare systems expanded rapidly globally. Community healthcare center modernization additionally increased by 22% during 2025 worldwide.

Digital reproductive consultation platforms additionally attracted 19% of healthcare technology investments globally. Postpartum contraceptive counseling initiatives additionally improved hospital insertion opportunities worldwide. Women aged 20 to 39 represented 61% of targeted reproductive healthcare investments because delayed pregnancy planning and workforce participation increased globally. Government-supported contraceptive education programs additionally expanded significantly worldwide.

New Product Development

New product development in the Intrauterine Contraceptive Devices (IUCDs) Market focuses on improved insertion comfort, hormonal regulation efficiency, flexible device structures, and extended contraceptive duration globally. More than 41% of reproductive healthcare companies introduced enhanced low-discomfort insertion technologies during 2025 worldwide. Hormonal intrauterine devices represented 52% of new product launches because demand for reduced menstrual bleeding and long-term contraception increased globally. Flexible-frame copper devices additionally improved patient comfort by 23% during clinical adoption worldwide.

Digital patient tracking and reminder systems additionally increased by 18% because reproductive healthcare providers improved contraceptive follow-up management globally. Outpatient insertion kits additionally expanded gynecology clinic efficiency worldwide. Biocompatible material innovation additionally improved insertion acceptance rates by 21% during 2025 globally. Postpartum-specific intrauterine device programs additionally gained strong healthcare provider attention worldwide.

Five Recent Developments

• In 2025, Bayer Healthcare expanded hormonal intrauterine device distribution across 18 additional reproductive healthcare markets globally.
• In 2024, Merck & Co. increased reproductive healthcare partnerships improving outpatient contraceptive access by 26%.
• In 2025, Fuji Latex Co. Ltd introduced improved flexible-frame contraceptive devices enhancing patient comfort by 19%.
• In 2023, Agile Therapeutics expanded women’s healthcare awareness campaigns increasing contraceptive counseling participation by 21%.
• In 2024, Pfizer strengthened reproductive health education programs across urban healthcare centers worldwide.

Report Coverage of Intrauterine Contraceptive Devices (IUCDs) Market

The Intrauterine Contraceptive Devices (IUCDs) Market report provides comprehensive analysis of hormonal intrauterine devices, copper intrauterine devices, reproductive healthcare infrastructure, gynecology services, and contraceptive accessibility trends globally. The report evaluates hospitals, gynecology clinics, and community healthcare centers involved in contraceptive insertion procedures worldwide. Copper intrauterine devices represented 61% of total global demand during 2025 because affordable non-hormonal contraception remained highly preferred globally. Hormonal intrauterine devices accounted for 39% because reduced menstrual symptoms and long-term birth control convenience strengthened adoption worldwide.

Regional analysis covers Europe with 34% market share, North America with 29%, Asia-Pacific with 26%, and Middle East & Africa with 11%. The report additionally evaluates postpartum insertion programs, digital reproductive healthcare consultations, same-day contraceptive procedures, and rural healthcare outreach globally. Hospitals accounted for 48% of insertion procedures because advanced gynecological infrastructure remained highly concentrated in hospital systems worldwide. Competitive analysis additionally covers reproductive healthcare companies, contraceptive manufacturers, outpatient gynecology providers, and community healthcare organizations shaping the Intrauterine Contraceptive Devices (IUCDs) Market between 2023 and 2025.